Roche Wins European Approval for Susvimo in Neovascular AMD
RHHBY sits 40% above its 52-week low of $39.5 on light trading volume (0.4× avg).
Summary
Roche received European approval for Susvimo, its implantable ranibizumab delivery system, for neovascular age-related macular degeneration. This expands the drug's market beyond the U.S., where it was approved in 2021 but faced manufacturing issues. The approval is a positive regulatory milestone for Roche's ophthalmology portfolio, though the commercial impact will depend on pricing and uptake in Europe.
At the time of this announcement, RHHBY was trading at $55.36 on OTC in the Life Sciences sector, with a market capitalization of approximately $346.2B. The 52-week trading range was $39.50 to $60.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.